Revolution Medicines
RVMD
255 hedge funds and large institutions have $7.74B invested in Revolution Medicines in 2024 Q3 according to their latest regulatory filings, with 55 funds opening new positions, 92 increasing their positions, 64 reducing their positions, and 21 closing their positions.
162% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 21
44% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 64
18% more capital invested
Capital invested by funds: $6.54B → $7.74B (+$1.2B)
14% more funds holding
Funds holding: 223 → 255 (+32)
0.09% more ownership
Funds ownership: 102.07% → 102.16% (+0.09%)
0% more funds holding in top 10
Funds holding in top 10: 18 → 18 (0)
64% less call options, than puts
Call options by funds: $13.2M | Put options by funds: $36.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$79.8M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$67.9M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$65.2M |
| 4 |
JP Morgan Chase
New York
|
+$44.5M |
| 5 |
Goldman Sachs
New York
|
+$39.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$109M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$98.4M |
| 3 |
AI
Alphabet Inc
Mountain View,
California
|
-$45.8M |
| 4 |
AG
Artal Group
Luxembourg
|
-$39.4M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$31M |
RVMD Hedge Fund Activity: Q3 2024 in Review
255 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q3 2024, worth a combined $7.74B — up 18% from $6.54B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new RVMD positions and 21 closed out — a net gain of 34 holders — while 92 added to existing stakes and 64 trimmed.
The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $79.8M. The largest seller was BVF Inc, cutting an estimated $109M.
- 255 institutional investors held Revolution Medicines (RVMD) as of Q3 2024, up from 223 in Q2 2024.
- Funds reported $7.74B of Revolution Medicines stock for Q3 2024, up 18% quarter-over-quarter.
- 55 funds opened new Revolution Medicines positions in Q3 2024 and 21 closed out, a net change of +34 holders.
- The largest Revolution Medicines buyer in Q3 2024 was Lord, Abbett & Co, an estimated $79.8M added.
- The largest Revolution Medicines seller in Q3 2024 was BVF Inc, an estimated $109M sold.
Based on aggregated 13F filings for Q3 2024.